3D Biotek, LLC

Based on its 3D Precison Microfabrication and 3D cell culture technologies, 3D Biotek has developed a novel Bioactive Tissue Matrix Equivalent technology platform aimed at replacing human/animal tissue derived matrix.  The first targeted application is for bone repair with the aim to eliminate the need to use auto- and allo- grafts such as illia crest and demineralized bone grafts. The development of this innovative technology platform was funded through both NIH’s SBIR phase I and Edison R&D grants. The objective of this presentation is to present 3D Biotek’s core technology and its current and future products for attracting potential business partnership, venture capital or corporate investment. External investment is needed in marketing of our current products and developing future medical device products.

 

AcquiSci Inc., a privately-held NJ corporation, incorporated in December 2007, is developing its medical device-based technology with an anti-inflammatory therapeutic platform known as d-OSAB™(doseable-Oxidative Stressed Autologous Blood) that will appreciably widen the present window of treatment for ischemic stroke.  The device has applications for clinical indications where inflammation is an underlying cause of disease, including Chronic Heart Failure, and as a purification process for the production of pathogen-free biologics, i.e. the inactivation of infectious prions, the rogue protein attributed to Mad Cow and Creutzfeldt-Jakob diseases.  The Company’s core technology patent (7,736,494) was issued by the USPTO in June 2010 and there are patents pending.  There is an equipment component and disposables for treatment. Both are revenue sources for the Company.  For stroke, the Company is embarking on clinical trials in India, CE marking, followed by EU clinical trials.  The Company intends to penetrate the US stroke market through the FDA/IDE/PMA process.

 

AltheRx Pharmaceuticals Inc.

AltheRx Pharmaceuticals Inc. is a focused clinical development company, engineered to progress specific acquired assets to commercialization through partnerships. With recent bio-pharma strategic R&D rationalizations and difficult economic issues facing many small companies, products and technologies with significant market potential are not being progressed. AltheRx evaluates these opportunities to secure the most promising products and progress them through clinical development and regulatory approval for profitable market penetration. Our goal is to develop products to a level, which makes them attractive for a bio-pharma partner, for full commercialization of the product. We are currently progressing, a highly differentiated Phase 2-b asset, Solabegron, acquired from GSK for Overactive Bladder (OAB). We have attracted the world’s foremost key opinion leaders in OAB for our scientific advisory board to assist us in the development and commercialization of Solabegron as a multi-billion dollar product.
 

 

AngioLab, Inc.

AngioLab, founded in 1999, is a biotechnology company focusing on the development of angiogenesis inhibitors.  The Company is engaged in the discovery, development, and commercialization of anti-angiogenic candidates to inhibit the abnormal growth of new blood vessels.

 

Ansaris   

 

Ansaris is a leader in fragment-based drug discovery underpinned by its unique proprietary platform technology that solves contemporary small molecule drug discovery challenges. The Ansaris approach has identified novel drug candidates for previously intractable targets and for targets that have failed using high-throughput screening.  Our approach can enable the ‘rescue’ of stalled programs by identifying hotspots for protein-protein interactions, allosteric sites for enzymes, and functionally selective protein conformations. Ansaris’s robust platform has been successfully applied to target classes such as kinases, proteases, phosphatases, and cell surface receptors in several therapeutic areas. Ansaris actively seeks partners for both engaging in discovery collaborations and advancing its drug development pipeline.

 

Applied Separations, Inc   

 

Applied Separations is the leader in Supercritical Fluid technology and application.  Our goal is to broadly apply the Supercritical Fluid technology to as many biotechnology applications as possible.
 

 

 

Augmenta is dedicated to the development of its enabling technology platform to enhance the potency of human and veterinary vaccines, both prophylactic and therapeutic.  The company will also develop its technology for clearing toxins from the blood and to enhance immunization of mice and other species to produce custom monoclonal and polyclonal antibodies. Augmenta will develope its own vaccine products, while also licensing its technology to others.

 

 

BioNanomatrix, Inc. (“BNM”) is developing game-changing, proprietary technologies for analysis of large biological molecules, such as nucleic acids that are extremely important in life science research, clinical diagnostic applications and development of therapeutics. Our core technology, based on an exclusive, worldwide license from Princeton University, is a disposable nanochannel array device (the “nanoAnalyzer® Chip”) that permits the fast, efficient, and cost-effective processing, labeling, detection, and analysis of very long segments of DNA. Our products provide users with the means to perform single-molecule analyses on minute biological samples that are essentially impossible, impractical, or too expensive with current technology. Furthermore, the nanoAnalyzer Chip can be tailored to address a wide array of distinct applications and will enable BNM to generate multiple, high margin and sustainable revenue streams from diverse customers including academic institutions, research institutes (e.g. genome centers), clinical laboratories, and pharmaceutical and diagnostics companies.

 

Boryung Pharmaceuticals is a division of the Boryung Group that is focused on R&D, Sales & Marketing and manufacturing of drugs related to the digestive system, circulatory system and the endocrine system, anticancer and anti-infection.  The company primarily operates in South Korea, where it is headquartered in Seoul and employs around 891 people. 

 

The company produces products in three categories: APIs, finished products and licensed products. Boryung is exporting various kinds of APIs products developed by our own technology including doxorubicin hydrocholride, epirubicin hydrochloride, captopril, alacepril, nitrendipine, fluconazole, ondansetron hydrochloride, tamsulosin hydrochloride, glimepiride, alibendole, torsemide, donepezil and topiramate.

 

The company's finished products in the therapeutic class of antibiotics, cardiovascular and antineoplastics are three major sources of Boryung’s revenue. We have also been distributing amino acids injections and dialysis solutions as the number one distributor in Korea.

 

Cernostics, Inc.   

 

The vision of Personalized Medicine requires new and improved clinical testing platforms to produce better predictive and prognostic molecular diagnostic tests.   New approaches will leverage the vast amount of new genetic, genomic and proteomic information from the Human Genome Project and other initiatives.   New approaches to cancer treatment will require looking at the tumor microenvironment for both drug targets, and novel biomarkers that are enable more predictive, preventative, and personalized healthcare. Cernostics is a personalized medicine company that develops and commercializes novel molecular diagnostics tests for anatomic pathology and tissue diagnostics, primarily focused in oncology.  Series A financing was completed in May, 2010, resulting in an investment of $2.7 million in cash and in-kind donations.  Lead investors include Geisinger Health System Foundation, Novitas Capital, Pittsburgh Life Science Greenhouse, and Ben Franklin Technology Partners.  We now seek our next round of financing to take the company to the next level. We are platform agnostics, and our proprietary technology allows simultaneous evaluation of multiple protein, DNA, or RNA biomarkers in the tumor micro-environment on a single slide.  Typical anatomic pathology tests typically evaluate a single marker, leaving large amounts of molecular information untapped.   Cernostics’ vision includes thorough evaluation of the tumor microenvironment.

 

Diamyd Incorporated

Diamyd is a biopharmaceutical company in the field of diabetes. Today the company's research and development concentrates on autoimmune diabetes and complications related to diabetes. The company's vision is to one day be able to prevent and cure the autoimmune form of diabetes. The goal is to be able to treat children, adolescents and adults with diabetes and to vaccinate in order to prevent the disease from breaking out. After several years of successful research and good results we now know that the diabetes vaccine Diamyd® significantly slows the disease process, which gives hope to diabetes patients.
 

Discovery Laboratories, Inc.   

 

Discovery Labs is a biotechnology company focused on the development of novel, therapeutic surfactant replacement therapies with potential broad application across many respiratory diseases. Surfactant is essential for normal breathing throughout life. Our fully-synthetic surfactant technology platform has the potential to establish a completely new therapeutic approach for the treatment of respiratory disease, with a targeted initial application in preterm infants. Our company has one focused goal – to create life-saving medications for patients with respiratory disease in order to advance the standard of care for pulmonary medicine. We provide our dedicated employees with a rewarding work experience, work side-by-side with the healthcare community and create value for our shareholders.

 

DoseCue   

 

DoseCue circuitry attaches to medication containers for two purposes: to issue automatic reminders at dose time and to track medication compliance automatically – without adding steps to patients’ dose-taking routine. For clinical trials, analysis of drug efficacy is informed by automatically logging dosing date & time data. For commercial products, DoseCue’s proven compliance increase improves patients’ outcomes, which reduces their total healthcare costs, and boosts revenue in the pharmaceutical supply chain.

 

Edge Therapeutics Inc   

 

Edge is a private, New Jersey based specialty pharma company who believes that local and sustained-release delivery of medicine directly to the injury site will prevent certain delayed complications, improve patient outcomes, and reduce healthcare costs. By transforming well-established off-patent drugs, Edge streamlines the development path and drastically reduces risk and cost. This abbreviated and de-risked path allows investors to recognize an attractive investment multiple within 3-4 years. Edge’s lead product, NimoGel, has the potential for U.S. sales to exceed $500MM and will soon be entering into its IND-enabling study.

Esperance Pharmaceuticals   

 

Esperance Pharmaceuticals is developing a new class of targeted anticancer drugs that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cell's surface. The drugs kill even those cells known to be resistant to chemotherapeutic drugs.

EyeGene, Inc.

EyeGene, Inc. is a Korean proteomics & Biopharmaceutical venture company, which is developing the Therapeutics, Diagnostics and Technology in eye-related disease & Vaccines.  The Chief Executive Officer, WonilYoo, founded EyeGene in Korea after extensive research & development at the CPRI (CJ Pharmaceutical Research Institute). The Company was incorporated in June 2000, focusing on the development of new therapeutics and diagnostics in eye-related diseases such as diabetic retinopathy (DMR) and retinopathy of prematurity (ROP). In  addition, the Company is developing “Super Biosimilar”vaccines such as an HPV vaccine for preventing cervical cancer with a novel immune stimulator (adjuvant).   EyeGene, Inc. is developing therapeutics for pressure ulcer, EG-Decorin with HUONS and a preventing vaccine for cervical cancer, EG-HPV with CHONGKUNDANG Pharmaceuticals Corp.

 

Ezose Sciences, Inc   

 

Ezose Sciences Inc. is a leading Glycomics-focused company that leverages GlycanMap® analysis, its unique, high-throughput glycan analysis technology in two ways:  1) as a platform to discover & develop new disease biomarkers and therapeutic targets and 2) as a service to support biologics drug development & manufacture and other R&D activities. A United States company, Ezose Sciences was founded in 2009 upon technology born from a leading academic glycomics research team at Japan’s prestigious Hokkaido University, in collaboration with and funded by two major Japanese-based global healthcare companies: Shionogi & Co., Ltd and Sumitomo Bakelite Co., Ltd. Ezose Sciences is headquartered in Pine Brook, New Jersey where it has 12 staff and occupies 12,000 square feet of fully-equipped laboratory and office space.

Immunome, Inc.    

 

Immunome is a discovery stage life science company with a patented native, human antibody platform which enables us to harness the natural curative power of the human immune system.   We believe that the very best therapeutic antibodies are those made by the human immune system and not by conventional, artificial systems such as mice or bacteria.  We are using this game-changing technology to develop novel therapies for infections which currently have no options.

 

In Silico Biosciences   

 

“Getting better medications faster to the right patients in schizophrenia and Alzheimer’s disease using computer-based mechanistic modeling as a translational tool”. We have developed an unique computer-based mechanistic disease modeling platform for use as a translational tool in CNS Drug Discovery & Development, notably in the area of Alzheimer’s disease, Parkinsons’s disease and schizophrenia. Unlike animal models of the disease, the model is calibrated using a large number of clinical data on tested drugs, including negative data. The platform is used by pharma companies to improve clinical success rates of candidate drugs in those CNS diseases by addressing specific key issues along the whole Drug Discovery & Development project timeline. In parallel, using the well calibrated platform in reverse, we have identified a set of 3 non-dopaminergic receptors that when combined with modest D2R antagonism, based on our model simulations, will likely result in clinical outcomes that are superior to the current best medication in schizophrenia. We have currently identified two hits from a ligand-based in silico screening approach with interesting multi-target profile and have started a Drug Discovery project.

 

KRICT is the only government-supported research institution in chemical technology of Korea. Since its establishment in 1976, KRICT has contributed to the growth of the domestic chemical industry and is now endeavoring to develop key chemical technologies to secure a sustainable future for the planet and its people.  KRICT seeks to improve the competitiveness of the chemical industry and promote the establishment of new national scale industries by developing and disseminating original chemical technologies and relevant convergence technologies; and by managing the public chemical technology infrastructure.

 

 

LZ Therapeutics works to develop therapeutics which will improve outcomes for neurodegenerative disorder patients, including improved symptom control and potential disease modification. The first area of therapeutic focus is Parkinson's disease.

 

Makefield Therapeutics, Inc   

 

Makefield Therapeutics, Inc., founded in July 2009, is a privately held therapeutics company with two development programs addressed to very large market opportunities in anti-infectives and the treatment of erectile dysfunction, both based on an innovative nanoparticle drug delivery platform with the potential to generate a pipeline of additional novel therapeutics. The Hybrid Nanoparticles™ have for the first time enabled the delivery of nitric oxide gas (NO) in a local, controlled and sustained manner. The platform is also capable of delivering peptides, siRNA and traditional small molecule pharmaceuticals both as single therapeutic entities and in combination treatments as well. The Company’s vision is: To develop a range of products based on the Company’s proprietary and enabling “Hybrid Nanoparticle”™ technology platform leading to creation of a significant and sustainable business enterprise.

 

Molecular Detection, Inc.   

 

Molecular Detection Inc. (MDI) is developing and commercializing a portfolio of sample-to-answer Detect-Ready molecular diagnostic tests for detection of infectious diseases.  Our first product is a ready-to-use rapid detection DNA-based screening test for MRSA infection that is in the market and full-time hospital use in the European Union.  It offers the advantages of increased accuracy, faster time to results and more efficient utilization of hospital resources compared to current and emerging MRSA diagnostic products. MDI’s tests are based on novel-patent pending technologies for differential diagnosis, chemistry, and for room temperature stabilization of the kit. MRSA infection is a growing problem worldwide and proactive inpatient screening programs are increasingly being adopted as the most effective means of controlling this dangerous and costly pathogen.

 

 

Molecular Targeting Technologies, Inc. (MTTI) is a Pennsylvania-based biotechnology company primarily focused on the development of small molecules for the molecular imaging of cardiovascular diseases and cancer. We have licensed a number of proprietary technologies that allow us to target glioma and prostate cancers as well as stroke and Parkinson disease. MTTI is also advancing a therapeutic human monoclonal antibody for Rabies post-exposure prophylaxis and Fusion Protein Technology for development of a Botulinum neurotoxin vaccine. In addition, MTTI is building a research reagents business for an immediate revenue stream and currently offers a range of innovative fluorescence based products for in vitro and in vivo research applications.

 

NPS Pharmaceuticals   

 

NPS Pharmaceuticals (Nasdaq: NPSP) is a New Jersey-based biopharmaceutical company focused on the development and commercialization of specialty therapeutics for rare gastrointestinal and endocrine disorders of high unmet medical need.  The company is currently conducting two Phase 3 registration studies.  Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for parenteral nutrition dependent short bowel syndrome and in preclinical development for pediatric indications and chemotherapy-induced gastrointestinal mucositis.  NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone therapy for hypoparathyroidism.The company’s proprietary programs are complemented by a royalty-based portfolio, which includes royalties on (i) Amgen’s sales of Sensipar® (cinacalcet HCl), (ii) Nycomed’s sales of Preotact® (parathyroid hormone 1-84 [rDNA origin] injection), (iii) Kyowa Hakko Kirin’s sales of REGPARA® (cinacalcet HCl) in Japan and (iv) Ortho-McNeil’s sales of Nucynta®.  The company’s royalty rights related to Sensipar, Preotact and REGPARA currently secure non-recourse debt. 

 

Onconova   

 

Onconova Therapeutics, Inc. (OTI) discovers and develops novel patented products for cancer therapy and cell protection.  Three products are in clinical development and the lead compound ON 01910.Na (ESTYBON™) is entering a pivotal Phase 3 trial. The first indication for ESTYBON™ is in Myelodysplastic Syndromes (MDS).  Based on promising clinical data from four major centers in the US, a pivotal trial has been planned and a Special Protocol Assessment (SPA) is being sought. This indication has been designated as “orphan” by the FDA. The pivotal trial will be supported by a $10 Million award from the Leukemia & Lymphoma Society® (LLS).  A second indication for ESTYBON™ in pancreatic cancer is advancing to a randomized clinical trial in Q4-2010. Onconova has a second product, Ex-RAD™, which is being developed in collaboration with the US Department of Defense (DOD). The first indication, prophylaxis against the harmful effects of radiation , is in advanced development under the FDA “animal rule”, where no Phase 2 or 3 clinical trials are required for product approval. The DOD has provided $10 Million in support of this program. Onconova has raised more than $100 Million, including $72 Million in equity financing. More than 100 patents cover the clinical and preclinical stage products and technologies. A robust pre-clinical pipeline and a platform technology support three clinical stage programs. Onconova is based in New Jersey (Princeton) and Pennsylvania (Newtown) and currently employs 23 full time personnel who focus on product and business development. Research is conducted in a network of affiliated programs based in Academic and Government laboratories, where more than 30 scientists work on our programs.

 

 

PhaseBio is a clinical stage product development company using its proprietary ELP biopolymer technology for creating novel and improved biopharmaceuticals.

 

PhDiagnostics, Inc   

 

Biotech company that desires to sell the entire portfolio for women's health.

 

 

Acornex is a privately-held pharmaceutical venture company dedicated to the discovery, development, and commercialization of drugs to treat brain and neurodegenerative diseases such as brain cancers by utilizing novel molecular transporters which are uniquely capable of crossing the blood-brain barrier.  Acornex also focuses on evelopment transporters that can target intracellular-organelles like mitochondria.
Acornex was founded in 2004 by Professor Sung-Kee Chung, a highly accomplished bioorganic and medicinal chemist in both the US & Korea. Its main office is within Maryland's I-270 technology corridor, a location that is capable of providing an opportunity for collaboration with the National Institutes of Health (NIH) and ready access to the Food and Drug Administration (FDA). The platform technologies and products now under development are the results of research being carried out primarily in Dr. Chung's laboratories at Pohang University of Science & Technology (Postech) in Korea in collaboration with many researchers around the world. 

 

 

Profectus Biosciences’ drug discovery group develops inhibitors targeting Rel proteins in the nuclear factor kappa-B (NF-κB) pathway as an alternative to the current proteasome inhibitor and TNF antagonists for treating cancer and inflammation. The aforementioned proteasome inhibitor and TNFα antagonists, which act upstream of the NF-κB pathway, produce significant side effects, including pain, nausea, and increased risk of infections. Direct NF-κB inhibition at the downstream Rel targets may provide a more effective, safer, and patient-friendly approach to treating such conditions. The Profectus drug candidates have been designed to interfere with the Rel proteins common to both the canonical and non-canonical NF-κB paths, in contrast to IκB-kinaseβ inhibitors, which only inhibit the canonical path.  We intend to develop first-in-class Rel inhibitors that include an intravenous dual inhibitor of the canonical and non-canonical pathways of NF-kB as a chemotherapeutic agent, and an oral inhibitor of c-rel as an anti-inflammatory agent. 

PTC Therapeutics, Inc.   

 

PTC Therapeutics, Inc. (PTC) is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC has assembled proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities. PTC's current pipeline of clinical and preclinical product candidates addresses multiple indications, including genetic disorders, oncology and infectious diseases.

 

The Health-Care Industry is poised for a revolution in diagnostics.  The key barrier is the persistent problem with false-positives for increasingly sensitive devices.  Typically, dialing back sensitivity introduces false negatives.  Our solution is to engineer digital molecular meters that eliminate both false positives and false negatives while maintaining highly sensitive detection.  This solution is based on patented and proprietary molecular technology co-developed with the Rutgers Laboratory of Prof. Kenneth J. Breslauer. 

The company is leveraging this technology to develop cost-effective  personal health monitors that quantify infectious organisms and personal health biomarkers.  Applications include rapid, and highly accurate point-of-care diagnosis under emergency situations, and sensitive, highly accurate and cost-effective prenatal screening for genetic diseases, based on minimally invasive sampling of the mother’s blood.

 

Recro Pharma, Inc   

 

Recro Pharma, Inc. is a specialty pharmaceutical company which develops solutions for managing serious pain and related conditions. The first Recro Pharma product is a product for serious pain, such as cancer pain. Recro Pharma is focused on clinical-stage assets which, with some careful regulatory strategy and well-planned clinical trial(s), cost-effectively address an unmet clinical need. Such products have clear market opportunities and will be viewed as attractive opportunities, whether for Recro Pharma to out-license or for direct commercialization.

 

 

Samyang has established a unique position in the pharmaceutical industry as a company specialized in drug delivery systems; oral drug delivery, parenteral drug delivery and transdermal drug delivery; and the Samyang Group of companies are developing advanced drug delivery systems and medical devices using its in-depth experiences in polymer chemistry and collaborative relationships with academic institutions and companies in Korea and the US. As Samyang's Pharmaceutical Business Unit incorporates new drug delivery technologies enabling effective delivery of various types of drugs to specific target sites, the most recent application involves a set of proprietary polymers that enable the sustained delivery of bio-pharmaceuticals.

 

SK Life Science Inc.

SK Life Science is a global development-stage pharmaceutical company focusing on drug discovery and development.  Our mission is to grow into a global pharmaceutical company specializing in products to treat CNS disorders. The company has R&D facilities in Korea, China, and the US. SK Life Science initiated research in 1993 in the CNS area and was the first Korean-based company to successfully file an IND in the US in 1996.  Since then, the company has filed a total of 10 INDs for drugs for the treatment of anxiety, depression, epilepsy, neuropathic pain, and schizophrenia. Three of these compounds have been partnered to global major pharma partners. Through SK Life Science’s Custom Manufacturing Service, it has cGMP-capable manufacturing capacity and is a preferred provider for key intermediates of global products marketed by major pharma companies.

TherimuneX Pharmaceuticals   

 

Our core belief is that many of the chronic idiopathic diseases have an infectious etiology.  As a result of our discoveries in the initiation and control of inflammation, TherimuneX Pharmaceuticals is advancing new therapeutic strategies for (i) the prevention of hospital-acquired infections and (ii) the treatment of chronic diseases arising from persistent infections. With federal funding from NIH/NIAID SBIR-AT grant “A Modulator of Innate Immunity for Preventing Hospital-Acquired Infections,” TherimuneX is developing its lead drug candidate, acALY-18, as the first “pathogen-agnostic” anti-infective agent. We have established efficacy of acALY-18 in a mouse model for hospital-acquired MRSA infections and provided preliminary safety data. We also discovered that acALY-18 inhibits HBV replication and promotes virion clearance in primary human hepatocytes and are currently evaluating acALY-18, in cooperation with the NIH, to determine the effective dose using a transgenic mouse model of chronic HBV infection. We have recently developed a second drug candidate that significantly reduces collagen expression in skin fibroblasts derived from Scleroderma patients.

Tobira Therapeutics, Inc   

 

Tobira has licensed worldwide, exclusive rights to two CCR5 antagonists (TBR-652 and TBR-220) from Takeda Pharmaceutical Company Limited for the development, manufacture and commercialization of these compounds for HIV and inflammatory diseases. CCR5 antagonists block entry of HIV into the host cell by blocking the CCR5 receptor (R5).  "TBR-652, Tobira s lead compound, has the potential to be best in class due to its once a day (QD) dosing, strong therapeutic index and low level of cross resistance compared to other entry inhibitors.  In addition, TBR-652 may have anti-inflammatory applications as it has CCR2 inhibition properties. To date, TBR-652 has been tested in over 180 healthy volunteers. TBR-652 has been presented its Phase 2a proof of concept, multiple dose-escalating study that evaluated the antiviral activity, safety, and pharmacokinetics in HIV infected, antiretroviral treatment-experienced patients who have not previously been treated with a CCR5 antagonist. Results from this Phase 2a study were presented at CROI 2010 and also at eh IAS in Vienna July 2010. Tobira has also obtained from Kureha Corporation the right to evaluate and negotiate a license for worldwide rights to a CXCR4 antagonist scaffold. CXCR4 antagonists are complimentary compounds to CCR5 antagonists and a brand new class of drugs to combat HIV. In light of the recent discontinuation of vaccine programs, a drug combination including Tobira's CCR5 and CXCR4 antagonists has the potential to be an ideal candidate for HIV/AIDS prophylaxis for the following reasons: 1) prevents viral entry of both R5 and X4 viruses, and 2) mimics natural immunity to HIV (individuals lacking the R5 receptor by inheriting a defective gene do not get infected with R5 virus).

 

Unigene

Unigene Laboratories, established in 1980, is a publicly traded biopharmaceutical company specializing in the development of peptide-based therapeutics.  We offer proprietary technologies for the manufacturing and delivery of peptide based drugs.  The recombinant manufacturing technology provides cost effective scalable production of peptides.  The oral peptide delivery technology and nasal delivery technologies provide an alternative route of administration that can increase patient acceptance and compliance leading to better market capture.  Unigene has several internal peptide based therapeutic programs available in the areas of osteoporosis, osteoarthritis, obesity/satiety, inflammation, cardiac reperfusion injury.

Vicept Therapeutics, Inc   

 

Vicept Therapeutics is a privately held, specialty biopharmaceutical company with a mission to develop novel products that address key unmet needs for patients with dermatologic conditions.  Vicept’s lead asset is positioned to be the first effective topically applied therapy directed towards the facial erythema (redness) of rosacea. The company is also pursuing the development of topical agents for the treatment and prevention of actinic purpura (bruising on back of arms often seen in elderly patients) and peri-procedural bruising (bruising associated with injectable procedures) of the skin.

 

ViroMed Co., Ltd.

ViroMed Co., Ltd. is a leading biotechnology company whose mission is to discover and develop innovative biopharmaceuticals for human diseases. ViroMed’s numerous achievements since its inception demonstrate that it is one of the most scientifically advanced R&D companies in today’s global biopharmaceutical industry. The company has differentiated itself from other competitors with its core technology and seasoned management.

ViroMed is headquartered in Seoul, Korea with a US presence in the San Francisco Bay Area. The company has assembled a diverse pipeline of novel biologic and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with twelve clinical trials ongoing in the US, Korea, and China. ViroMed is publicly held with a listing on the KOSDAQ stock exchange (084990).

 

Vitae Pharmaceuticals, Inc.

Vitae is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets with significant unmet medical needs, including chronic kidney disease, diabetes, Alzheimer’s disease  and atherosclerosis.